Consensus conference. Treatment of hepatitis C.
This conference was organized according to the methodological rules published by the Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). The conclusions and recommendations contained in this document were written, in full independence, by the jury of the conference. ANAES is in no way accountable for these views.
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000150:complications; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001835:Body Weight; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006084:Graft Rejection; D015658:HIV Infections / Q000150:complications; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications; D016031:Liver Transplantation; D008297:Male; D001523:Mental Disorders / Q000150:complications; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011788:Quality of Life; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D019966:Substance-Related Disorders / Q000150:complications; D013997:Time Factors
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons; D000547:Amantadine